Kexing BiopharmEN
NEWS AND INFORMATION
Home / News / News and information / Kexing Biopharm...

Kexing Biopharm: A leader in China Recombinant Protein Therapeutics Industry

Article source:Kexing BiopharmOct 29,2024View: 1136

In the heart of China's biopharmaceutical landscape, Kexing Biopharm stands as a pioneer and a leader, dedicated to the industrialization of genetic engineering drugs. With a mission to "rejuvenate the country through science and education, serve the country through industry, and strengthen the country with health," Kexing Biopharm has embarked on a transformative journey in the genetic engineering drug industry since its inception.


A Legacy of Innovation and Excellence


Over the decades, Kexing Biopharm has etched its mark on the annals of time with a series of innovative strides. The company's evolution reflects the dynamic growth of the biopharmaceutical sector, with Kexing Biopharm at the helm, scripting a brilliant chapter in the life and health industry. As it continues to meet unmet clinical needs, the company's mission has pivoted to "lprecise products, predictable effects, health protection," underscoring its commitment to developing high-quality biological drugs and enhancing their clinical value, thereby safeguarding human health and aiming to becoming the leader in high-quality biologics.


Addressing Clinical Needs with Precision and Care


Kexing Biopharm's approach is deeply rooted in understanding the needs of medical professionals and patients. The company persists in drug research and development, backed by a comprehensive drug production quality management system. Through process optimization and continuous improvement, Kexing Biopharm ensures and enhances drug quality, aiming to deliver higher clinical value and more precise treatment drugs to doctors and patients.


The Essence of Lean Pharmacy and Causal Treatment


Lean pharmacy represents the initial step in addressing the needs of the medical community and patients. Kexing Biopharm goes beyond by focusing on causal treatment and symptomatic medication, which are pivotal to the efficacy of drugs and the health of patients. By gaining insights into the usage scenarios of doctors and patients and adhering to strict evidence-based medical research, Kexing Biopharm ensures that the use of medicines is safer, more effective, more accurate, and more convenient.


Global Expansion and Strategic Partnerships


Kexing Biopharm's vision is not confined within national boundaries; the company is actively expanding its global footprint. With a presence in nearly 70 countries worldwide, Kexing Biopharm has been deeply engaged in overseas markets for over 20 years. The company continuously improves and expands its commercial layout in emerging markets, with overseas subsidiaries such as Brazil, Mexico, Singapore, Egypt, and Vietnam as pivot points, deeply radiating and covering the entire overseas commercial marketing matrix of Central America, South America, Southeast Asia, the Middle East, North Africa, and other regions.


Investing in the Future of Biopharmaceuticals


Kexing Biopharm's commitment to innovation is evident in its research and development investments. In 2022, the company invested 193 million RMB in R&D, showcasing a growth of 57.21% compared to the previous year. This investment has led to the progression of several products from development to clinical stages, including humanaα1b Interferon inhalation solution, and long-acting recombinant human G-CSF, and a human growth hormone injection. 


Building a Robust Product Portfolio


Kexing Biopharm's product portfolio is a testament to its dedication to serving global patients. The company's flagship products, such as EPOSINO, have gained significant market share and customer recognition for their exceptional quality across multiple countries. Kexing Biopharm is also proactively promoting China's biosimilars abroad, including drugs like Albumin paclitaxel (Apexelsin), Infliximab, Adalimumab, Bevacizumab, Trastuzumab, Liraglutide, Naratinib Maleate , Lenalidomide, Sevelam Carbonate, Elibulin Mesylate, Sorafenib, Pembrolizumab, Olaparib, etc.


Conclusion


Kexing Biopharm's journey is a story of innovation, commitment, and a relentless pursuit of excellence. As the company continues to expand its global reach and enhance its product offerings, it remains steadfast in its mission to protect human health and becoming the leader in high quality biologics. With a forward-thinking approach and a focus on meeting the unmet needs of the medical community, Kexing Biopharm is not just shaping the future of biopharmaceuticals but is also contributing to a healthier world for all.


LABEL:
Related News